|
시장보고서
Pfizer
Pipeline * Products * Performance * Potential
|
Abstract
Headquartered in New York, Pfizer has been the world' s largest research-based
pharmaceutical company since it stole Merck & Co' s crown in 1998. The
subsequent acquisition of Warner-Lambert (and with it Agouron) in June 2000
and the merger with Pharmacia in April 2003 (which included the former
Monsanto division, GD Searle) cemented this position. Furthermore, in January
2009, the company announced plans to acquire Wyeth, another leading global
pharmaceutical company, in a deal valued at around US$68 billion, which should
help the company maintain a leaderhsip position in the longer-term.
Pfizer has a broad portfolio, with strengths in the areas of cardiovascular
disease, central nervous system disorders, inflammatory disease, metabolic
disorders, infectious diseases and oncology.
Employing over 81,000 people worldwide, it has more than 100 overseas
subsidiaries and operations in around 150 countries.
Pfizer believes it has one of the broadest product portfolios of all the major
pharmaceutical companies. In 2004, Pfizer set an industry record with ten of
its products (including Celebrex) generating revenues of more than US$1
billion each; in 2008 this number was reduced to nine.
This new strategic analysis report Pfizer: Pipeline - Products -
Performance - Potential, provides a complete and critical review of the
company and includes unique and independent assessments and forecasts of key
products. Buyers of the web edition receive online access for one year via an
easy-to-use interface with fast navigation and a full text search facility.
All formats are the same price.
Table of Contents
- EXECUTIVE SUMMARY
- Introduction
- Current F inancial Position
- Company Performance
- Business Segment Performance
- Geographic Segment Performance
- Company Strategy
- R&D Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product Performance F orecast
- Pipeline Analysis
- Discontinued R&D Projects
- Conclusions / Outlook
- THERAPEUTIC AREA F OCUS
- R&D PIPELINE
- CARDIOVASCULAR / METABOLISM
- Marketed Products
- Champix
- Lipitor
- Norvasc
- Others
- R&D Projects
- Apixaban
- NOX-B11
- PF-734200
- Growth Forecast
- CENTRAL NERVOUS SYSTEM
- Marketed Products
- Aricept
- Geodon/Zeldox
- Lyrica
- Zoloft
- Others
- R&D Projects
- Dimebon
- PF-4360365
- PF-4856880
- PF-4856881
- S,S-reboxetine
- TS-032
- Growth F orecast
- INFECTIOUS AND RESPIRATORY
- Marketed Products
- Eraxis/Ecalta
- Selzentry/Celsentri
- Vfend
- Zyvox/Zyvoxa
- Others
- R&D Projects
- R343
- Sulopenem
- TT-033
- UK-453061
- Zeven
- Growth Forecast
- UROLOGY
- Marketed Products
- Detrusitol/Detrol
- Toviaz
- Viagra/Revatio
- R&D Projects
- Growth Forecast
- ARTHRITIS AND PAIN
- Marketed Products
- R&D Projects
- ADL5747
- ADL5859
- CCR2 Antagonists
- CP-690550
- Tanezumab
- Growth Forecast
- ONCOLOGY
- Marketed Products
- R&D Projects
- Axitinib
- CovX 060
- Figitumumab
- PD-325901
- PD-332991
- PF-3512676
- PF-4949568
- Growth Forecast
- OPHTHALMOLOGY
- Marketed Products
- Xalatan/Xalcom/Xalacom
- Others
- R&D Projects
- Growth Forecast
- ENDOCRINE DISORDERS
- Marketed Products
- Growth Forecast
- WOMEN' S HEALTHCARE
- Marketed Products
- R&D Projects
- Growth F orecast
- OTHER
- Marketed Products
- R&D Projects
- APPENDIX 1 - FINANCIAL PERFORMANCE
- APPENDIX 2 - KEY CORPORATE EVENTS
- APPENDIX 3 - KEY AGREEMENTS
- Adolor Corporation
- Allergan
- Almirall SA
- Astellas Pharma Inc.
- Aurobindo Pharma/Claris Lifesciences Ltd.
- Auxillium Holdings Inc.
- Bausch & Lomb Inc.
- Bayer Schering Pharma
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celldex Therapeutics
- Coley Pharmaceutical Group Inc.
- Cytos Biotechnology AG
- Eisai
- Elusys Therapeutics
- Five Prime Therapeutics Inc.
- Genentech Inc.
- GlaxoSmithKline
- Graceway Pharmaceuticals LLC
- Hydra Biosciences Inc.
- Icagen Inc.
- Immunicon Corporation
- Incyte Corporation
- International Partnership for Microbicides
- Isis Pharmaceuticals Inc.
- Lavipharm Co
- Ligand Pharmaceuticals Inc.
- Kosan Biosciences
- Medarex Inc.
- Medivation Inc.
- Melior Discovery Inc.
- Merck KGaA
- NicOx SA
- NovaMed Pharmaceuticals Inc.
- Novocell
- Noxxon Pharma AG
- Odyssey Thera Inc.
- Onyx Pharmaceuticals Inc.
- OSI Pharmaceuticals Inc/New York University
- Quark Pharmaceuticals Inc.
- Recordati
- Renovis Inc.
- Rigel Pharmaceuticals Inc.
- Sigma-Tau Pharmaceuticals Inc.
- Silence Therapeutics
- Tacere Therapeutics
- Taisho Pharmaceutical
- TransTech Pharma
- UCB
- Others
- APPENDIX 4 - I NFRASTRUCTURE
- Manufacturing Facilities
- R&D F acilities
- APPENDIX 5 - KEY PHARMACEUTICAL
- SUBSIDIARIES/JOINT VENTURES
- Subsidiaries
- Joint-venture Companies
- APPENDIX 6 - PRODUCT INDEX
INDEX OF TABLES
- Principal Operating Results
- Capital Expenditure By Business Area
- Sales By Business Area
- Operating Income By Business Area
- Identifiable Assets By Business Area
- Sales By Destination
- Long-Lived Assets By Geographical Area
- Key Patent Expiry Dates
- Recent Product Approvals
- Sales By Therapeutic Area/Major Products
- Breakdown Of Cardiovascular/Metabolic Product Sales
- Major Cardiovascular/Metabolism Products, 2008
- Breakdown of CNS Sales
- Major CNS Products, 2008
- Breakdown of Infectious Disease/ Respiratory Sales
- Major Infectious & Respiratory Products, 2008
- Breakdown of Urology Sales
- Major Urology Products, 2008
- Breakdown of Arthritis/Pain Sales
- Major Arthritis and Pain Products, 2008
- Breakdown of Oncology Sales
- Major Oncology Products, 2008
- Breakdown of Opthalmology Sales
- Major Ophthalmology Products, 2008
- Breakdown of Endocrine Sales
- Major Endocrine Disorder Products, 2008
- Breakdown of Other Product Sales
- Major Other Products, 2008
- Pfizer' s Major Manufacturing Sites
INDEX OF CHARTS
- Sales, Costs and Operating Income
- R&D Expenditure & Capital Expenditure
- Capital Expenditure By Business Area
- Sales By Business Area
- Operating Income By Business Area
- Sales By Destination
- Employees and Productivity
- Sales of Current Top Ten Products (2003A-2013E)
- Sales By Therapeutic Area
- Top Selling Products, 2008
- Champix Sales (2006A-2013E)
- Lipitor Sales (2003A-2013E)
- Norvasc Sales (2003A-2013E)
- Apixaban Sales (2010E-2014E)
- Aricept Sales (2003A-2013E)
- Geodon/Zeldox Sales (2003A-2013E)
- Lyrica Sales (2004A-2013E)
- Zoloft Sales (2003A-2013E)
- Selzentry/Celsentri Sales (2007A-2013E)
- Vfend Sales (2003A-2013E)
- Zyvox Sales (2003A-2013E)
- Detrol/Detrol LA Sales (2003A-2013E)
- Viagra Sales (2003A-2013E)
- Celebrex Sales (2003A-2013E)
- Sutent Sales (2006A-2013E)
- Sales Forecast (2010E-2015E)
- Xalatan/Xalcom Sales (2003A-2013E)
- Genotropin Sales (2003A-2013E)
- Fablyn Sales (2010E-2015E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
